• Knightscope’s shares began trading publicly on the Nasdaq Global Market on January 27, following the closing of a public offering that kicked off in early December
• Following the public offering, Knightscope has entered its 2nd chapter as it continues to work toward making the U.S. the safest nation in the world
• The company has now created a dedicated investor deck to help inform prospective and existing Knightscope investors

Roughly 90% of women and 60% of men visit companies’ investor relations (“IR”) websites when researching a new investment opportunity. These statistics, uncovered by PR Newswire’s Vintage Division in its 2016 Shareholder Confidence 365 Study (https://ibn.fm/Ky87z), are complemented and reinforced by insiders’ observations that a company’s IR website is one of the most important sources of information for investors (https://ibn.fm/tz4QR). The IR website, they say, should not be overly complex. Instead, it should have user-friendly navigation, with key content reachable using just a few clicks, and offering simple data summaries. dTo this end, Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies, has rolled out a dedicated simplified IR site (https://ibn.fm/ihdBE) linking directly to the company’s investor presentation and CEO’s video introduction to the latest shareholder meeting. This site augments Knightscope’s general investor overview information offered as a tab on the company’s main website, featuring Knightscope’s story, investor updates, news, events, presentations, corporate governance, financial information, stock information, and IR resources. Knightscope’s shares were first announced to be listed on the Nasdaq Global Market in early December (https://ibn.fm/lkMjS), kick-starting a public offering that raised over $22.3 million through the sale of 2,236,619 shares of the company’s Class A Common Stock as of January 26 (https://ibn.fm/VKcQ3). Trading on NASDAQ commenced on January 27, 2022. “We’ve brought on thousands and thousands of new investors in Knightscope as we embark on the 2nd chapter of a very long book in helping to make the United States of America the safest country in the world. I am forever grateful for our relentless team and the 28,000+ investors that helped write the 1st chapter in our journey,” commented Knightscope Chairman and CEO William Santana Li following the closing of the public offering. The company intends to direct the net proceeds of the offering toward the scaling of its current fleet of Autonomous Security Robots (“ASRs”), which includes the K1, K3, and K5, as well as simultaneously investing in new technologies. With these proceeds, Knightscope’s 2nd chapter appears well underway, driven by investors, for whom the intuitive, simple, well-structured, and informative IR website is intended. Since its inception in 2013, Knightscope has leveraged investments from its supporters – to the tune of more than $100 million, according to its latest presentation (https://ibn.fm/3umH7) – with the amount going toward building all the crime-fighting technology from scratch. In addition to its ASRs, the company also offers the Knightscope Security Operations Center (“KSOC”) user interface, data storage, analytics, and charging systems, which are collectively anchored in a Machine-as-a-Service business model. The KSOC user interface enables security professionals to monitor multiple locations, manage patrol schedules, sound alarms, communicate via two-way intercoms, as well as watch and listen to the happenings around the ASRs. Knightscope has a recurring revenue business model for a recurring societal problem of crime, and is well poised to continue to grow with its portfolio of advanced physical security technologies. For more information about Knightscope (NASDAQ: KSCP), visit the company’s website at www.Knightscope.com, and if you have a need for a subscription service, you may request a private demonstration of the technology at www.Knightscope.com/demo.  NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP

• Company announced the first officially issued patent
• Patent provides strong protection for Cybin’s growing IP portfolio of psychedelic-based compounds
• CYB004 has demonstrated potential efficacy at lower doses while increasing duration of drug effect that may alleviate common negative experiences

In a milestone moment for psychedelic therapeutics company Cybin (NEO: CYBN) (NYSE American: CYBN), the company has announced its first official issued patent. The U.S. Patent and Trademark Office (“USPTO”) has granted U.S. patent 11,242,318 to Cybin’s proprietary CYB004, the company’s lead investigational proprietary DMT compound. “From the outset, Cybin has focused on creating differentiated compounds that harness the potential efficacy of classical psychedelics, while addressing the known limitations necessary for these molecules to become approvable therapeutics,” said Cybin CEO Doug Drysdale. “We are extremely pleased to receive a composition of matter patent for CYB004, adding strong protection for our growing intellectual property portfolio of psychedelic-based compounds, supporting and protecting the investments that we are making in our CYB004 program. This patent is both rewarding and timely as we prepare to initiate a pilot study for CYB004 in the third quarter of 2022 and work tirelessly to develop an important and alternative treatment option for the millions of people suffering from anxiety disorders.” Under the patent, allowed claims include a range of deuterated forms of DMT and 5-MeO-DMT; the patent also covers composition of matter and protects the CYB004 drug substance as a putative new chemical entity until 2041, when the patent is set to expire. Most importantly, perhaps, the patent highlights the strength of Cybin’s IP position and the company’s differentiated approach to bringing a psychedelic-based therapy toward regulatory approval and to patients in an otherwise congested industry. Cybin has spent considerable time and resources developing CYB004, which has the potential to effectively treat anxiety disorders with improved control over DMT delivered through inhalation. Specifically, in preclinical trials, the proprietary DMT compound indicated reduced dosage for better safety as well as the potential for longer duration of effect while reducing negative experiences associated with current treatment methods. For more information on Cybin’s programs, visit their corporate presentation at the following link: https://ibn.fm/RzdzR. Looking forward, the company is planning a pilot study of CYB004; Cybin intends to submit a clinical trial application for the study in coming weeks with expectations to begin the study in Q3 of 2022. In addition, Cybin will follow up on multiple opportunities to secure and support its patent position for research and development evaluating deuterated tryptamines for future psychedelic-based treatments for mental illnesses. The market for Cybin’s newly patented CYB004 is vast, with the National Institute of Mental Health reporting that an estimated 19% of adults in the United States had any anxiety disorder in the past year and more than 31 of U.S. adults will experience any anxiety disorder at some point in their lives). With those numbers as a backdrop, the potential is high for Cybin’s innovative drug-delivery systems to change lives and establish the company as a leader in a billion-dollar industry Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, United Kingdom and Ireland. The company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• PlantX launched XFitness, an online fitness service that will be exclusive to XVIP members
• The service features classes that accommodate people from all age groups and can be enjoyed either individually or as a group
• XVIP members will also enjoy discounts on the PlantX store, free shipping, and premiere access to the company’s special events and product launches, among other perks
• PlantX also announced the completion of an oversubscribed non-brokered private placement of 52,296,660 units of the company at CAD$0.105 per unit

PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF), since its inception, has remained committed to being the digital face of the plant-based community. In addition to over 5,000 plant-based products in its portfolio, the company also seeks to educate its consumer base while also engaging in community-building efforts. Its efforts are geared towards enriching people’s lives, growing and empowering the plant-based community. In a recent move that affirms this commitment, PlantX announced the launch of its new online fitness service- XFitness. This service will cover programs and activities that include but are not limited to cardio, yoga, high-intensity interval training, meditation, boxing, martial arts, strength-based and functional fitness (https://ibn.fm/wi1he). This new program will be accessible to XVIP members, a newly-launched membership program that opens PlantX customers to a growing list of benefits and exclusive membership offers. These benefits include PlantX coupon codes, 5% off all purchases on the PlantX platform, and 10% off when using an instructor coupon code. XVIP members will also enjoy free shipping on all PlantX orders, in addition to premier access to the company’s special events and product launches. “We have created PlantX to be a plant-based brand and our vision aims to enrich people’s lives not just through plant-based education, but also by promoting general health, fitness and wellness,” noted Sean Dollinger, the Founder of PlantX. “The XFitness vertical is a crucial component of this vision, as it helps our community gain access to fun and interactive fitness classes, connect with like-minded individuals and learn how to create an integrated plant-based routine to enhance their overall health and wellbeing,” he added. XFitness classes are structured to accommodate people from all age groups, including children and the youth. It is also an adaptable fitness platform where members can enjoy and participate individually or as a group. The goal is to have PlantX customers access high quality, fun, and effective fitness resources, which, in turn, will holistically enrich their plant-based health and wellbeing. “As PlantX continues to grow, we are committed to consistently improving the experience and satisfaction of our growing community,” reckoned Lorne Rapkin, PlantX’s Chief Executive Officer (“CEO”). “The XVIP membership plan includes an upgraded and more attractive range of exclusive benefits that increases value and boosts our customers’ enjoyment for PlantX products and services. Through XVIP, we hope to repay our customers’ loyalty more fully,” he added. Plant X also announced the completion of an oversubscribed non-brokered private placement of 52,296,660 units of the company at CAD$0.105 per unit. The approximate gross proceeds from the transaction stood at CAD$5,491,150, with the initial offer including the exercise of the company’s over-allotment option. Proceeds from the offering will be funneled into business development, general corporate purposes, and working capital. The securities issued in connection with the offering will be subject to a four-month hold period ending June 18, 2022, in accordance with applicable Canadian securities laws. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

Businesses, Industries, CEOs, liquidity providers, venture capitalists, economists, regulators, and people interested in blockchain trade are invited to attend the 8^th edition of Blockchain Africa Conference 2022, being held on March 17-18, 2022, as a virtual event organized by Bitcoin Events. Bitcoin Events is the pioneer events company to host world-class bitcoin and blockchain conferences in Africa. The Bitcoin Event conferences offer a global stage for industry leaders and influential personas of the cryptocurrency and blockchain industries. The dignitaries connect and discuss the future trends as well as the social, economic, and financial aspects of the global cryptocurrency economy. These speakers are eminent personalities who share insights and discuss how blockchain technology can be included in the mainstream finance for payments, remittance, and other business transactions in fields like renewable energy, remittances, farming and agriculture, community currencies and more. Conducting cryptocurrency in a safe and regulated environment where the digital assets of the users are secure, is one of the core issues at the Blockchain Africa Conference 2022. The panel will take up discussions on how businesses and people of South Africa can leverage Self-Sovereign Identity (“SSI”) and what are the hurdles involved in its successful adoption. As the current traditional identity systems are fragmented, insecure and exclusive, blockchain technology can be a boon owing to the secure management and tamper-proof infrastructure that ensures the safety of digital assets of enterprises, users and management systems. In a keynote address, Dr. Edward Obasi, COO, DafriGroup, PLC, will discuss how DafriBank Digital Limited (a Comoros licensed Digital Bank set up by DafriGroup) conducts banking, finance and crypto transactions in Africa and worldwide. Other discussions and sessions include in-depth insights into the Next Generation of Cross-Border Payments in Africa and how blockchain smart contracts are being leveraged and how they redefine the future of businesses. Blockchain is slowly gaining ground and has now become the preferred mode of financial transaction by many leading organizations. The Blockchain Conference Africa 2022 is a big step for transparency and understanding of this medium of transaction for seamless business management and the underlying challenges with infrastructure and regulatory frameworks to achieve these goals. This is in keeping with the goal of the conference that started with ‘Beyond the Hype’, ‘From Hype to Mainstream’ and now ‘Ready for Business?’ To learn more, please visit https://blockchainafrica.co/.

• App simplifies process of reading, studying and analyzing, allowing readers to stay on top of information they need to know
• “Forbes” claims multitasking masters are simply switching back and forth between two or more objects
• Relying on artificial intelligence rather than human intelligence, Pluaris can do a myriad of things simultaneously

Multitasking is a myth, declared a recent “Forbes” article, dashing the belief of overachievers everywhere who thought they had mastered the art of doing more than one thing at a time. However, while “Forbes” claims people are unable to multitask, Nowigence Inc. (NOWG) has developed an off-the shelf, cloud-based, artificial intelligence (“AI”) platform, called Pluaris(TM), that actually can successfully handle more than one task at a time. “Most of us, especially us Type A’s, like to think we’re great multitaskers,” states the article. “We check our email and text messages while listening in on a Zoom meeting, working on a spreadsheet, and scrolling Twitter or a news site. In this age of distraction, multitasking seems like a useful superpower to have. Unfortunately, it isn’t even real. That’s right — multitasking is a myth.” Instead, claims “Forbes,” what multitasking masters are actually doing is switching back and forth between two or more objects, which the publication calls “task switching.” “Often, there’s little rhyme or reason for the switching,” the article notes. “That’s especially the case when we let little distractions and ongoing worries interrupt our focus. When we’re task switching, we aren’t fully engaged in anything. Task switching can take a significant toll. You may be surprised to learn that toggling back and forth between tasks—even just taking 30 seconds to send a text—slows down and can even derail your mental ability for up to a full half hour afterward.” The article goes on to point out that task switchers often become more forgetful, dumber and more stressed out. While multitasking might not be a real thing, Nowigence’s Pluaris is. Relying on artificial intelligence rather than human intelligence, Pluaris can do a myriad of things simultaneously. The game-changing app automatically monitors public news sources for identified topics of interest while also gathering information together and providing summaries, extracting intelligence, and creating graphical analysis. It’s the ultimate multitasking platform. And while Pluaris automates reading and analysis of textual data, the app’s users can focus on one thing: learning more in less time. The app simplifies the process of reading, studying, and analyzing, allowing readers to stay on top of the information they need to know. Simplifying learning is what Nowigence is all about. The company is committed to helping individuals, teams and enterprises quickly distill knowledge from massive amounts of textual data, both public and private. By integrating state-of-the-art data processing techniques in an intuitive interface at an affordable subscription price, Pluaris puts the power of data science into the hands of consumers. For more information, visit the company’s website at www.Nowigence.com. NOTE TO INVESTORS: The latest news and updates relating to Nowigence are available in the company’s newsroom at https://ibn.fm/NOW

• Over 140 rare cannabinoids exist in the cannabis plant – some with the potential to have more therapeutic benefits than those cannabinoids found prominently in the plant
• InMed and subsidiary BayMedica plan to release several rare cannabinoid products in the first half of 2022
• Combination of complementary InMed and BayMedica business models key to increasing shareholders’ value

In 2020, the global health and wellness market reached $4.436 trillion and is expected to grow at a CAGR of 5.5% from 2021 to 2030, resulting in an estimated value of $7.7 trillion by the end of the forecasted period (https://ibn.fm/BjCNi). The primary driver for the market is the rise in chronic diseases globally. The lifestyles led by individuals have resulted in a high prevalence of stress, depression, anxiety, cancer, diabetes, and other health-related issues. On top of these conditions, the lack of a proper diet has reduced the intake of essential minerals and nutrients required for healthy function by every body. The rapid growth of the biopharmaceutical industry and the constant research and development of health and wellness products boost the medicinal industry with life-saving drugs and treatments for some of the most devastating illnesses and diseases. Six areas make up a consumer’s view of wellness – better health, better fitness, better nutrition, better appearance, better sleep, and better mindfulness. According to a McKinsey & Company survey, worldwide, the most money spent was on products that promote better health (https://ibn.fm/Jhzpl). The majority of the spending (70%) was product-related, but over the next year, the services industry is expected to grow as well. InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and the manufacturer of technologies for pharmaceutical-grade rare cannabinoids, has dedicated itself to developing new therapeutic alternatives for the treatment of conditions with high unmet medical needs. Together with its subsidiary, BayMedica, InMed increases shareholder value by combining two complementary business models. There are over 140 rare cannabinoids that naturally occur at low amounts in the cannabis plant. InMed initially focused on the therapeutic benefits of cannabinol (“CBN”), which shows increased potential over other cannabinoids more prominently found in the cannabis plant. CBN is also the active pharmaceutical ingredient in two lead programs conducted by InMed for dermatological (INM-755) and ocular (INM-088) diseases. The manufacturing process used by InMed and recently acquired subsidiary BayMedica is unparalleled in the industry. There is no “one-size-fits-all” approach to cannabinoid manufacturing, so multiple avenues are required to realize the maximum outcome for the targeted cannabinoid. InMed and BayMedica, like a well-oiled machine, work together using biosynthesis, chemical synthesis, and the proprietary IntegraSyn(TM) manufacturing models. Biosynthesis is preferred for complex structures at a large scale and is well suited for the consumer and health industry. Chemical synthesis is preferred for cannabinoids with simple structures and offers the potential for less equipment and lower capital requirements. There is also a potential for easier validation with chemical synthesis, and it is also an important component of secondary IntegraSyn(TM) differentiation steps. IntegraSyn(TM) utilizes high-efficiency biosynthesis-derived enzymes, allowing the flexibility to shift from the production of one cannabinoid to a range of cannabinoids. This proprietary method makes it easy to scale up to mass production, it is commonly available, and it is cost-efficient when dealing with startup materials. Together, InMed and BayMedica plan to launch a series of rare cannabinoids into the health and wellness sector during Q1 2022, starting with cannabicitran (“CBT”). “We are delivering on our objective to launch additional rare cannabinoids in early 2022 in response to inbound demand,” BayMedica SVP and General Manager Shane Johnson said (https://ibn.fm/lsr3m). “By midyear, we expect to have at least four rare cannabinoids available for the health and wellness markets, positioning us as a leading large-scale supplier of high-quality rare cannabinoids in these sectors.” For more information, visit the company’s website at www.InMedPharma.com. NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

• INND continues to broaden its reach to help more of the 70 million individuals in North America who suffer from hearing loss
• Company deploys multichannel market strategy involving e-commerce and in-store presence to help consumers access hearing aids
• With a full range of good quality yet affordable hearing aid solutions targeted at its large and growing market, INND believes it can experience significant growth potential over the coming months

With nearly 16% of adults in the US reporting hearing trouble, the total addressable market of InnerScope Hearing Technologies (OTC: INND), a leading manufacturer, distributor, and retailer of FDA-Registered hearing aids, appears to be vast (https://ibn.fm/qD3tv). And as the population continues to age, the number of people that can benefit from hearing help is only expected to grow. To reach this large and ever-growing market, INND leverages a robust omnichannel market strategy to help an estimated 70 million people in North America that have some hearing impairment. This well-rounded and carefully executed strategy utilizes wholesale and retail distribution networks and DTC (direct-to-consumer) channel that involves InnerScope’s MyHearIQ.com eCommerce site and partner sites such as FSAstore.com, HSAstore.com, and WellDeservedHealth.com. In February, INND launched a new eCommerce website for HearingAssist, its wholly-owned subsidiary, located at https://hearingassist.com/. HearingAssist has been an established leader in the DTC hearing aid market since 2008. It is known as Walmart’s largest hearing aid supplier, with products available in 757 of its stores nationwide and over 500,000 hearing aids sold to date. INND also offers free self-check hearing screening in its kiosks installed in national pharmacy chains, big-box retailers, and national and local groceries chains. In December 2021, INND announced a deal with Giant Eagle, one of the country’s largest grocery and pharmacy chains with more than 470 locations in Pennsylvania, Ohio, West Virginia, Maryland, and Indiana. The agreement allows INND to initially deploy its proprietary hearing kiosks in six locations, with more to come (https://ibn.fm/hnzhn). INND continues to add new in-store hearing kiosks as part of its strategic rollout with multi-billion-dollar grocery and pharmacy retailers. As a veteran in the retail hearing aid space, with its founders who have over 70 years in the business, INND offers hearing aids that are FDA-registered, medical-grade devices. They come with professional remote programming and support from licensed hearing professionals through INND’s proprietary HearIQ App (available to download Free on Apple App Store and Google Play). INND also launched a new call center designed to deliver a superior personalized customer experience and elevate the support it provides to customers as it continues to accelerate nationwide growth. INND remains committed to empowering consumers to take control of their hearing care from the comfort of their homes by delivering the same quality of hearing technology and expert support as traditional providers but at a fraction of the cost. INND also offers a monthly subscription payment option that allows users to purchase hearing aids and get bi-annual free upgrades, making hearing care even more affordable. With its portfolio of innovative yet affordable hearing solutions targeted at the market that is expected to expand, INND is confident that there is a significant market opportunity for the company to experience explosive growth potential over the next 6 to 12 months (https://ibn.fm/xjThr). For more information, visit the company’s website at www.INND.com. NOTE TO INVESTORS: The latest news and updates relating to INND are available in the company’s newsroom at https://ibn.fm/INND

• Global diabetes-related healthcare expenses are estimated at $966 billion in 2021
• A recent report reveals 537 million adults currently live with diabetes, projected to rise to 643 million by 2030 and 783 million by 2045
• Glucose intake is an important factor in diabetes management, prevention and reversal
• NMRD’s sugarBEAT(R) wearable is a non-invasive, flexible CGM device helping diabetes and prediabetes patients monitor glucose levels
• NMRD’s MiBoKo metabolic health program recently launched, provides AI-powered insights based on glucose readings

Diabetes is a primary driver of chronic disease costing the healthcare services sector more than $966 billion in 2021. Nemaura Medical (NASDAQ: NMRD), a medical technology company that develops affordable diagnostic and digital tools for chronic disease management, is positioned to address the problem with sugarBEAT(R), a wearable, non-invasive and flexible Continuous Glucose Monitor (“CGM”) that can help diabetes and prediabetes patients monitor glucose levels to manage, prevent, and possibly reverse the disease. According to the International Diabetes Federation (“IDF”), diabetes is, “spiraling out of control.” The organization recently released a report detailing the disease’s progress, revealing that 537 million adults live with diabetes, a number projected to rise to 643 million by 2030 and 783 million by 2045. Besides affecting the health and wellbeing of patients, employers and insurers are burdened with diabetes-related expenses, currently estimated at over $966 billion – a 316% increase over the last 15 years. Nemaura addresses this through its flagship sugarBEAT(R) wearable CGM device and companion mobile app that provides helpful disease management insights. Unlike other CGM devices, sugarBEAT(R) is non-invasive and doesn’t require insertion of the sensor inside the skin: Users can now choose the days they wear the patch instead of a prolonged continuous-wear period lasting up to 14 days. Combined with MiBoKo, the company’s recently launched metabolic health program, both products provide valuable AI-powered insights that NMRD management believes will benefit one-third to half of the diabetes market. “A person’s response to sugar intake can influence many factors, from appetite and body weight, to sleep patterns, energy levels and even mood, not to mention also being a considerable factor in chronic diseases like diabetes, heart disease and dementia,” said NMRD CEO Dr. Faz Chowdhury. “With MiBoKo, we can extend our proprietary non-invasive device and sensor technology and interactive lifestyle and AI coaching programs beyond the traditional diabetes market and into an adjacent, yet separate, market application of metabolic health. At Nemaura, we continue to look for the intersection of patient comfort and convenience through an advanced and unique technology that addresses significant healthcare needs for large patient populations. We believe that MiBoKo offers insights into metabolic health in a user-friendly way unlike any other program on the market.” Founded in 2011, NMRD initially developed a single platform technology to measure blood markers at the skin’s surface. Since then, the company evolved its technology to address the global need for wearable glucose-monitoring devices, intersecting the diabetes, pre-diabetes, and weight loss markets. With several filed and pending patents, and significant trade secrets covering its technology platform, Nemaura is favorably positioned to lead the market with cost-effective, wearable, and non-invasive diabetes management devices. For more information, visit the company’s website at www.NemauraMedical.com. For more information on Miboko, visit www.Miboko.com. NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

• Cepton makes public debut after completing business combination with GCAC; appears on track to deliver on its vision to expand leading market position and drive value for stakeholders
• With initial market capitalization of around $1.4 billion, Cepton more than doubled its last private valuation of $615 million
• Company has grand plans for future; aims to be the one to extend LiDAR technology adoption from the luxury sector to mainstream

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance MMT(R) LiDAR solutions, made its Wall Street debut on February 11, 2022, following the successful completion of its previously announced business combination with Growth Capital Acquisition Corp. (“GCAC”), a Delaware special purpose acquisition company (or SPAC). The combined company has been renamed Cepton, Inc. with common stocks and warrants trading on the Nasdaq Capital Market under the ticker symbols “CPTN” and “CPTNW”, respectively. It will continue to be led by the current Cepton management team, including Dr. Jun Pei, Cepton’s Co-Founder and CEO, bolstered by George Syllantavos, co-CEO of GCAC, who will serve as a director of Cepton (https://ibn.fm/bAZnC). “Today is a special milestone for Cepton,” stated Dr. Jun Pei, Cepton’s Co-Founder and CEO. “We founded Cepton with the goal of enabling safe and autonomous transportation for everyone, and today’s announcement is another step in making that vision a reality. As a public company, we remain focused on the goals of mass-market LiDAR adoption in consumer vehicles and expanding our market leadership position while driving value for all of Cepton’s stakeholders.” George Syllantavos, co-CEO of GCAC, stated, “We are thrilled with the successful completion of this business combination. Cepton is a company at the forefront of technological advancements with the largest known ADAS LiDAR series production award in the industry and ongoing engagements with all of the Top 10 global OEMs. We are excited about the future and continuing to support the company in its public phase.” “I am impressed by the elegant technical solutions that Cepton is bringing to the lidar industry in addressing automotive ADAS needs. I’m certain that Cepton’s solutions will gain further commercial success in automotive and other markets. Time works in Cepton’s favor now that its public life has begun, and its vision is on track to materialize,” concluded Akis Tsirigakis, co-CEO of GCAC. As a Silicon Valley innovator of LiDAR-based solutions for automotive (ADAS/AV), smart cities, smart spaces, and smart industrial applications, Cepton is known for its patented Micro Motion Technology (MMT(R)), which allows for a balanced approach to performance, cost, and reliability. This innovative rotation-free, mirrorless, and frictionless technology enables Cepton to tackle challenges that currently restrict the applicability of LiDAR solutions to ultra-high-end vehicles only. Here, Cepton seems poised to deliver where others appear to have failed. Led by industry experts with decades of combined experience across advanced LiDAR and imaging technologies, Cepton set its eyes on taking LiDAR mainstream, focusing on the mass market commercialization of high performance, high-quality LiDAR solutions. Cepton and its tier-1 manufacturing partner, Koito manufacturing of Japan, was awarded the largest known series production award in the lidar industry by General Motors in support of its Ultra Cruise program. GM’s Ultra Cruise program will enable true hands-free driving across 95 percent of driving scenarios, covering more than 2 million miles of roads at launch in the United States and Canada, with the capacity to grow up to more than 3.4 million miles. Customers will be able to travel truly hands free with Ultra Cruise across nearly every road including city streets, subdivision streets and paved rural roads, in addition to highways. For more information, visit the company’s website at www.Cepton.com. NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

July 29th-31st, 2022 Venue: LOS ANGELES, CALIFORNIA To be held from July 29th to the 31st, NFT Expoverse is set to become the largest event focused on the mass adoption of blockchain technologies, aiming to attract a large number of renowned companies and personalities from the industry. Tickets, booth space, and sponsorship are all available. The event will showcase a broad spectrum of blockchain-related technologies such as Defi, dApps, P2E gaming, AR, VR, and the metaverse and welcome companies from any industries, including sports, gaming, retail, and entertainment, aiming to employ such technologies. From superior-technology brand stands to mammoth video walls to live-streaming speaker sessions, NFT Expoverse will have it all, defining itself as an interactive user-focused event showcasing some of the best and current blockchain-related projects. Recently joined exhibitors and sponsors include Tokenframe, Lunar, Charli3, Niftify, and the Cardano Defi Alliance. Blockchain technologies open up a world of possibilities, among them the ability to mint what is known as NFTs (Non-fungible tokens). These are blockchain-based tokens that represent unique digital assets like art, music, videos, and gaming items. NFTs are encrypted with the creator’s signature and use blockchain software to verify the ownership and originality of the assets. Several creators from around the globe are preparing for an exciting opportunity to elevate their profession at NFT Expoverse, where users will witness the metaverses, experience digital wonders, and try new special blockchain-based innovations. NFT Expoverse is organized by a devoted team of experts who are putting together a dynamic event featuring global influencers in a fun and exciting way. The speakers at the event will be prominent figures, considered authorities in the field of blockchain, from NFT artists to blockchain software developers and industry entrepreneurs. These individuals will share in-depth knowledge through engaging and motivational blockchain-related speeches. With a robust networking platform, entrepreneurs and enthusiasts from different niches will come together and interact on a common floor at NFT Expoverse. Startups and new businesses will leverage the networking sessions to connect with leading stalwarts and develop business ties. Eminent personas will take the speaker stage to share insights and discuss important issues in their respective fields. Some of the featured speakers include John Kraski of NFT Genius, Ian Scarffe of Blockchain Founders Fund, Tejas Chopra of Netflix, Monica Long of Ripple, and many others will be joining. This engaging exposition is open to attendees with interviews, webinars, specials, and news from insights experienced uniquely. The show will be held in Los Angeles, a perfect venue for heads, enthusiasts, entrepreneurs, creators, and companies to network and learn from each other. At the event, attendees will have access to the refreshments and networking breaks, in addition to the sessions at the NFT event. Furthermore, the venue is located near hotels where attendees can book a comfortable stay. Finally, attendees will be able to participate in the immersive aspiring sessions and VIP participants will enjoy the exclusive after-party. For more information, please visit https://nftexpo.com/